On August 5, 2024 Radiopharm Theranostics (ASX:RAD) reported it has secured yet another milestone with a payment of AU$3.0 million (US$2.0 million) from Nasdaq-listed Lantheus Holdings Inc (Nasdaq:LNTH). This payment comes under their recent preclinical assets transfer and development agreement, announced on 20 June 2024.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under this agreement, Lantheus, a US-based player in the radiopharmaceutical sector, has committed to an initial equity investment of AU$7.5 million (US$4.99 million) in Radiopharm at 5 cents per share, representing a 47% premium over the share price at that time. Additionally, Lantheus has the option to invest a further AU$7.5 million (US$5.0 million) within the next six months under the same terms.
The agreement also includes a separate transfer and development component in which Radiopharm has assigned and sublicensed two of its preclinical assets to Lantheus. These include a TROP2 targeting nanobody and an LRRC15 targeting monoclonal antibody. These assets are valued at AU$3.0 million (US$2.0 million).
Riccardo Canevari, CEO & MD of Radiopharm Theranostics, expressed enthusiasm about the partnership, stating, "I am delighted with the confidence demonstrated by Lantheus in settling the transfer and development agreement and making this payment ahead of the shareholder meeting later this month. We are well advanced in our strategic planning with Lantheus, and the collaboration between our two companies augurs well for the future."
Lantheus’ investment funds will be allocated to general working capital, drug manufacturing, and clinical trials for Radiopharm Theranostics.
In June, Radiopharm announced the completion of an AU$70 million placement, featuring a strategic investment from Lantheus. Additionally, as per its recent update, RAD aims to achieve a secondary listing on NASDAQ by 2024 end.
(Press release, Radiopharm Theranostics, AUG 5, 2024, View Source [SID1234661592])